Stay updated with breaking news from Eur Thyroid. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Approval based on data from the COSMIC-311 Phase III trial, in which Cabometyx (cabozantinib) demonstrated a 78% reduction in risk of disease progression or death versus placebo1 This milestone
Approval based on data from the COSMIC-311 Phase III trial, in which Cabometyx® (cabozantinib) demonstrated a 78% reduction in risk of disease progression or death versus placebo1This milestone marks the first treatment option to be specifically approved as a second-line therapy in this indicationDisclaimer: Intende...
Ipsen announces European Commission approval of the use of Cabometyx® (cabozantinib) as a monotherapy for the treatment of adult patients
Recommendation based on data from the COSMIC-311 Phase III trial, in which Cabometyx (cabozantinib) demonstrated a 78% reduction in risk of disease progression or death versus placebo1 Disclaimer:
Ipsen Opts-in to Join Exelixis With Ongoing Development of Cabometyx for People Living With a Form of Thyroid Cancer, Based on Promising Interim Results 1 Detailed results will be presented at the upcoming 2021 American Society of Clinical Oncology (ASCO) Annual Meeting Participation in the collaboration will provide Ipsen with access to full trial data to support potential future regulatory submissions Disclaimer: Intended for international media and investor audiences only Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced it has exercised its option to collaborate with Exel...